Salt Lake City, Utah — Transformative research offering fresh insights and treatment advancements for age-related macular degeneration (AMD), the leading cause of blindness in adults over age 50, will be among the highlights showcased from May 4 - 8 at the Association for Research in Vision and Ophthalmology’s (ARVO) 2025 Annual Meeting in Salt Lake City, Utah.
AMD damages the central part of the retina, the macula, leading to vision impairment and in serious cases, loss of central vision. There are two main forms, dry AMD (atrophic), which is more common, and wet AMD (neovascular), which is less common but more severe. Currently, there are treatments that slow down the progression in both types, but no cures exist, making continued research vital.
At the Annual Meeting, scientists are presenting novel findings on factors that may contribute to AMD. This includes studies exploring how cellular changes in the eye might play a role, as well as possible links between AMD and commonly used drugs like metformin, commonly used for diabetes, and the body’s immune system. These insights could potentially lead to better diagnostic tools and treatment approaches.
Other research being presented examine the effectiveness of newly approved therapies, with results highlighting the risks and benefits. This information could guide clinicians in choosing the best course of care for their patients. While the search for a cure continues, these advancements offer hope for earlier detection, more personalized treatment and improved outcomes for those living with AMD.
##
The Association for Research in Vision and Ophthalmology (ARVO) is an international eye and vision research organization with more than 10,000 members from over 60 countries. Our Annual Meeting is the premiere global gathering for eye and vision scientists, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. For 2025, the Meeting will be hosted May 4 - 8 in Salt Lake City, Utah. The Meeting theme, i3: imagining innovation and intelligence in vision science, addresses how vision research is continually being transformed by new information and technologies that are catalyzing our research as we aim to treat, cure and ultimately prevent blinding eye diseases. Learn more at ARVO.org/AM.
Media contact:
Jenniffer Scherhaufer, MMC, CAE
1.240.221.2923
[email protected]
RSS